[{"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal\/Provincial\/Territorial Public Drug Plan Formularies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medexus Pharmaceuticals"},{"company":"KYE Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse\u00ae Available to LEMS Patients in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"KYE Pharmaceuticals"},{"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec\u2019s RAMQ List of Medications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medexus Pharmaceuticals"},{"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M\u00e9dunik Canada's Ruzurgi\u00ae Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MEDUNIK CANADA"},{"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aequus Pharmaceuticals"},{"company":"KYE Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"KYE Pharmaceuticals"},{"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"ImmunoFlex"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Aurinia Pharmaceuticals\u2019 LUPKYNIS\u2122 (Voclosporin) for Adult Patients with Active Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Data Showing LUPKYNIS Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia to Present AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS in Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Results From the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Enters Into License Agreement with Kal\u00e9o for The Canadian Rights to Allerject\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Valeo Pharma"}]
Details:
Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Lead Product(s):
Epinephrine
Therapeutic Area: Immunology
Product Name: Allerject
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
KALEO INC
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
August 02, 2022
Details:
LUPKYNIS (voclosporin) is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.
Lead Product(s):
Voclosporin
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 26, 2022
Details:
LUPKYNIS (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 20, 2022
Details:
LUPKYNIS (voclosporin) is first FDA-approved structurally modified calcineurin inhibitor for treatment of patients with active lupus nephritis, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 16, 2022
Details:
Lupkynis (voclosporin), is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 04, 2022
Details:
The interim analysis of AURORA 2 showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil Hydrochloride
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 20, 2021
Details:
Pooled data from the AURA-LV and AURORA 1 study demonstrate that LUPKYNIS, in combination with mycophenolate mofetil and low-dose corticosteroids, led to treatment benefits across biopsy class subgroups compared with treatment with MMF and low-dose corticosteroids alone.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil Hydrochloride
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 08, 2021
Details:
U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals' LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care.
Lead Product(s):
Voclosporin,Mycophenolate Mofetil
Therapeutic Area: Immunology
Product Name: Lupkynis
Highest Development Status: Approved
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 22, 2021
Details:
FLEX 10™ is ImmunoFlex's unique N-Acetyl-L-cysteine formulation in packs of 30 - 600 mg capsules. FLEX 10TM is a powerful antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.
Lead Product(s):
N-Acetylcysteine
Therapeutic Area: Immunology
Product Name: FLEX 10
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Chemistree
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 19, 2021
Details:
KYE Pharmaceuticals announces FIRDAPSE® (amifampridine phosphate), the first amifampridine product approved in Canada, is now widely available for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults.
Lead Product(s):
Amifampridine Phosphate
Therapeutic Area: Immunology
Product Name: Firdapse
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 28, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
